Total trials
743
Active
176
Phase 3
25
Total enrollment
128,616
Pipeline matrix
Showing 40 of 114 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Normal saline | — | — | — | — | 3 | ||
| Dexmedetomidine | — | — | — | — | — | 3 | |
| ActiveMatrix | — | — | — | — | — | 1 | |
| betamethasone valerate 0.1% cream | — | — | — | — | — | 1 | |
| Platelet-Rich Plasma (PRP) Injections | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Vevye® | — | — | — | — | — | 1 | |
| Cyclosporine emulsion | — | — | — | — | — | 1 | |
| Bupivacaine Hydrochloride | — | — | — | — | — | 1 | |
| Indocyanine Green (ICG)-Assisted Ureteral Identification | — | — | — | — | — | 1 | |
| Cytarabine | — | — | — | — | 2 | ||
| Vinblastine/prednisone | — | — | — | — | — | 1 | |
| Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric] | — | — | — | — | — | 1 | |
| Ferrous Sulfate 65 mg elemental iron | — | — | — | — | — | 1 | |
| Cytoxan | — | — | — | 9 | |||
| Proflavine Hemisulfate | — | — | — | — | — | 2 | |
| Psilocybin 15mg | — | — | — | — | — | 1 | |
| Psilocybin 25mg | — | — | — | — | — | 1 | |
| Durvalumab / tremelimumab | — | — | — | — | — | 1 | |
| Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab | — | — | — | — | — | 1 | |
| HPV vaccine, Imiquimod, and metformin combination therapy | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Folfirinox | — | — | — | — | — | 1 | |
| Albumin | — | — | — | — | — | 1 | |
| Tranexamic Acid 650 MG | — | — | — | — | — | 1 | |
| Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells | — | — | — | — | — | 1 | |
| Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation | — | — | — | — | — | 1 | |
| Recombinant human growth hormone | — | — | — | — | — | 1 | |
| Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2 | — | — | — | — | — | 1 | |
| Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2 | — | — | — | — | — | 1 | |
| Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2 | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | 23 | |||
| Cyclophosphamide | — | — | 19 | ||||
| C7R-GD2.CART cells | — | — | — | — | — | 2 | |
| 21.15.GPC3-CAR T Cells | — | — | — | — | — | 2 | |
| Fludara | — | — | — | — | — | 2 | |
| TAA-specific CTLs | — | — | — | — | 4 | ||
| Dose Level 1 | — | — | — | — | — | 3 | |
| Dose Level 2 | — | — | — | — | — | 3 | |
| GINAKIT Cells | — | — | — | — | — | 2 |
74 more active programs hidden
Next readouts
- 2011-11
- 2012-05-29
- 2012-07
- 2013-09
- 2014-07
- 2015-12
- 2016-04
- 2017-03
- 2018-07
- 2019-10
Top conditions
- Obesity20
- Substance Abuse14
- Depression14
- Cocaine Dependence12
- Obsessive-Compulsive Disorder11
- Neuroblastoma11
- Type 1 Diabetes10
- Anxiety10
Frequently asked questions about Baylor College of Medicine
- How many clinical trials does Baylor College of Medicine have on ClinicalTrials.gov?
- Baylor College of Medicine is listed as the lead sponsor on 743 clinical trials in ClinicalTrials.gov, 176 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Baylor College of Medicine's trials are in Phase 3?
- 25 of Baylor College of Medicine's trials are in Phase 3, spread across 114 active drug programs.
- What therapeutic areas does Baylor College of Medicine focus on?
- Baylor College of Medicine's most-studied conditions on ClinicalTrials.gov are Obesity, Substance Abuse, Depression, Cocaine Dependence, Obsessive-Compulsive Disorder.
- When are Baylor College of Medicine's next clinical trial readouts?
- Baylor College of Medicine has 10 upcoming primary-completion readouts tracked here; the soonest is “CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene”, expected around 2011-11.